NTLA - Intellia Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NTLA is currently covered by 20 analysts with an average price target of $41.94. This is a potential upside of $28.34 (208.38%) from yesterday's end of day stock price of $13.6.

Intellia Therapeutics's activity chart (see below) currently has 199 price targets and 195 ratings on display. The stock rating distribution of NTLA is 27.87% HOLD and 72.13% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 42.12% with an average time for these price targets to be met of 120.13 days.

Highest price target for NTLA is $68, Lowest price target is $9, average price target is $37.79.

Most recent stock forecast was given by WHITNEY IJEM from CANACCORD on 03-Jun-2025.

Currently out of the existing stock ratings of NTLA, 17 are a HOLD (27.87%), 44 are a BUY (72.13%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$54

$40.4 (297.06%)

$73

1 months 23 days ago
(03-Jun-2025)

0/5 (0%)

$46.31 (602.21%)

Hold

$10

$-3.6 (-26.47%)

$14

2 months 7 days ago
(19-May-2025)

9/11 (81.82%)

$0.94 (10.38%)

317

Hold

$10

$-3.6 (-26.47%)

$14

2 months 17 days ago
(09-May-2025)

5/8 (62.5%)

$1.88 (23.15%)

52

Buy

$68

$54.4 (400.00%)

$68

2 months 17 days ago
(09-May-2025)

3/13 (23.08%)

$59.88 (737.44%)

68

Buy

$13

$-0.6 (-4.41%)

$55

4 months 28 days ago
(28-Feb-2025)

1/5 (20%)

$2.14 (19.71%)

144

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NTLA (Intellia Therapeutics) average time for price targets to be met?

On average it took 120.13 days on average for the stock forecasts to be realized with a an average price target met ratio 42.12

Which analyst has the current highest performing score on NTLA (Intellia Therapeutics) with a proven track record?

GEULAH LIVSHITS

Which analyst has the most public recommendations on NTLA (Intellia Therapeutics)?

Geulah Livshits works at CHARDAN CAPITAL and has 11 price targets and 12 ratings on NTLA

Which analyst is the currently most bullish on NTLA (Intellia Therapeutics)?

Swapnil Malekar with highest potential upside - $149.4

Which analyst is the currently most reserved on NTLA (Intellia Therapeutics)?

Martin Auster with lowest potential downside - -$7.62

Intellia Therapeutics in the News

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on July 1, 2025, it awarded an inducement grant to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grant...

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?